Advanced Oncotherapy PLC (AVO) Stock Rating Reaffirmed by Beaufort Securities
Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “speculative buy” rating restated by equities researchers at Beaufort Securities in a research report issued on Monday.
Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 118.77 on Monday. The company has a 50-day moving average price of GBX 113.55 and a 200-day moving average price of GBX 140.30. The company’s market cap is GBX 67.38 million. Advanced Oncotherapy PLC has a 12-month low of GBX 98.00 and a 12-month high of GBX 217.25.
Advanced Oncotherapy PLC Company Profile
Advanced Oncotherapy Plc is a United Kingdom-based company. The Company is engaged in providing medical technology for cancer treatment and managing a health-related property. The Company operates in three business segments: Proton Therapy, Single Dose Intra-Operative Radiotherapy Treatment (SDIORT) and Healthcare related properties.
Receive News & Stock Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related stocks with our FREE daily email newsletter.